Tissue Regenix Share Price (TRX)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Tissue Regenix	LSE:TRX	London	Ordinary Share	GB00B5SGVL29	ORD 0.5P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.10p	+0.96%	10.50p	203,484	15:22:25
Bid Price		Offer Price	High Price	Low Price	Open Price
10.00p		11.00p	10.65p	10.40p	10.40p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	5.2	-10.8	-1.0	-	123.02

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Geiger Count. S (GCS), Port Erin (PEBI)

Tissue Regenix (TRX) Latest News

Tissue Regenix News

Date	Time	Source	Headline
19/4/2018	15:29	UKREG	Tissue Regenix Group PLC Holding(s) in Company
26/3/2018	17:17	ALNC	Tissue Regenix 2017 Loss Narrows As Revenue Rises Three-Fold
26/3/2018	07:24	ALNCF	Alliance News Flash Headline
26/3/2018	07:00	UKREG	Tissue Regenix Group PLC Annual results for period ended 31 December 2017
16/3/2018	16:21	ALNC	Tissue Regenix Says Trading Remains In Line With Expectations
16/3/2018	15:40	UKREG	Tissue Regenix Group PLC Publication of Financial Results
08/3/2018	07:15	RNSNON	Tissue Regenix Group PLC Hardman & Co: Full-year 2017 - what to look for
06/3/2018	13:13	ALNC	Tissue Regenix Unit Inks Distribution Agreement With Arthrex
06/3/2018	13:13	BW	CellRight Technologies Signs Multi-Year Distribution Agreement With..
06/3/2018	07:01	UKREG	Tissue Regenix Group PLC Long term distribution agreement with Arthrex, Inc

More Tissue Regenix News

Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Share Charts

1 Year Tissue Regenix Chart

1 Month Tissue Regenix Chart

Intraday Tissue Regenix Chart

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date	Time	Title	Posts
19/4/2018	15:51	Tissue Regenix delivering practical solutions to real clinical issues	2,064
14/3/2018	17:13	Torex - an insiders tale	24
24/5/2016	10:30	Third time lucky	6,918
29/6/2013	21:26	TOREX 2007 - THE TILLS RING AT LAST	8
24/9/2012	10:10	Torex Retailing	8

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

Date	Subject
22/4/2018 09:20	Tissue Regenix Daily Update: Tissue Regenix is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 10.40p. Tissue Regenix has a 4 week average price of 7.38p and a 12 week average price of 7.38p. The 1 year high share price is 16.50p while the 1 year low share price is currently 5.63p. There are currently 1,171,649,005 shares in issue and the average daily traded volume is 248,045 shares. The market capitalisation of Tissue Regenix is £123,023,145.53. Read Full Thread Reply
26/2/2018 07:17	channel pirate: 2 X RNS's today !! Let's hope we get some positive share price lifting results on 19th March then: 26/02/2018 7:01am UK Regulatory (RNS & others) Tissue Regenix (LSE:TRX) Intraday Stock Chart Today : Monday 26 February 2018 Click Here for more Tissue Regenix Charts. TIDMTRX RNS Number : 8568F Tissue Regenix Group PLC 26 February 2018 Tissue Regenix Group plc Notice of Results Leeds, 26 February 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces it will release its unaudited preliminary results for the year ended 31 December 2017 on Monday 19 March. Further information regarding an analyst call will follow in due course. For more Information: Tissue Regenix Group plc Tel: 0330 Caitlin Pearson Head of Communications 430 3073 / 07920272 441 ---------------------------------------- ------------ Jefferies International Ltd Tel: 020 Simon Hardy / Christopher Binks 7029 8000 ---------------------------------------- ------------ FTI Consulting Tel: 0203 Brett Pollard / Mo Noonan/ Rob Winder 727 1000 Read Full Thread Follow Reply
25/8/2017 20:52	channel pirate: Well the company are good at manufacturing tissue to repair / heal wounds etc, so maybe they ought to manufacture a positive RNS that will repair the share price which has been severely wounded over the past few months !! Read Full Thread Follow Reply
11/8/2017 15:05	andrewbaker: Adding to and following on from post 1934 in June, it's heartening to know that even a business that's not blessed with the best management, can become compelling when the product is really good and the share price way too low. What we really need is better figures, and better management; then this can really go. I'd buy more, but I'm already loaded to the gills, and can't destabilise my portfolio by doing so: so ... you guys drink your fill, and enjoy what should be, better late that never, a big rise northwards (and more northwards than before, too). ... Couldn't resist it: bought another 15,000 at 13.95p. I'm holding a heck of a lot more, so ok for this top-up, IMHO. lol. :) Read Full Thread Follow Reply
22/6/2017 09:52	channel pirate: With the share price having lost just over 35.36% in the last 6 months, then we could do with some good supporting news right now, or like "yesterday" and not "tomorrow". I have built a nice size holding during these past 6 months, but will not be panic selling or adding more until we get some positive news from the company. Read Full Thread Follow Reply
29/5/2017 07:49	channel pirate: Morning bamboo2, Guessing, then the new Holdings Company has been inaugurated to acquire acquisitions the Main Company has in their sights as being beneficial to the Main Company – hence the recent RNS regarding CellRight Technologies, LLC ("CellRight"). To me then this indicates the Company is getting “stronger̶1; all round and is expanding, generating more income etc, both of which has not yet been updated to the market. I would expect the large shareholders (Invesco, Woodford etc) are already briefed what is happening, especially with the share price languishing at the present low price, which must have knocked millions off the value of their holdings. I’m looking forward to the Prelims, and let’s hope it reassures us small pi’s also that we have “boarded the right train”. Read Full Thread Follow Reply
24/4/2017 12:54	channel pirate: Thought I would send an email to Investor Relations at the company this morning - will post the reply should I get one............. Good morning Caitlin, Being a shareholder with a six figure holding it is sad to see some shareholders exiting due to a falling share price and a lack of updates from the company. This time last year the company had already announced via the market of when it was going to report it’s Accounts & Report for the preceding year. Can you advise me of when we are likely to hear from the company in respect of progress and the last financial years Accounts. Thanking you in anticipation. Kind Regards, Read Full Thread Follow Reply
13/2/2017 15:33	channel pirate: Just been looking back through some of the company announcements over the last few months which re-assures me of my holding and maybe that on this dip, or subsequent dips, then it might be prudent to start adding again. From the announcement on 28th November : “The launch of OrthoPure™ XT remains on track for H1 2017, with CE mark approval in the same period. The first distribution agreements within Europe have been signed, indicators of the strong commercial and clinical support for OrthoPure™ XT, in preparation for rapid commercialisation in key European markets once approval is granted. Peter Hamer, Commercial Director TRX Orthopaedics Ltd: "We are extremely encouraged by the initial results returned from the study. Having entered our first distributor agreements, which highlight the demand and market opportunity for OrthoPure™ XT, we remain on track for launch of OrthoPure™ XT by the end of H1 2017.” So anytime in the next 4 months if all goes to plan, and that should see a significant rise in the share price if we are lucky ?? Read Full Thread Follow Reply
27/7/2016 07:08	multibagger: Hi Swiss Paul, Some very valid and searching questions. The biotech/healthcare product market is a very complex one due to various procurement and payment schemes/methods. In the UK, the NHS is a slow adopter and constrained by cost.The US is a much higher cost healthcare system and if TRX finds traction there, then there will be an uplift in share price. Though I keep an eye on TRX, I am not of the view that the share price will move upwards fast and not invested currently. I'm not a fan of either Odell or Samuels having met them both in Leeds at the AGM a few years ago, when I was the only shareholder present ! I'm not convinced about their their tech pipeline either, as regenerative medicine is moving a lot quicker than TRX are. I sold out not long after. My approach to biotech investing has changed and now largely go for funds....I hold AXA Framlington Biotech though I made good money from SCLP, SUMM and SAR in the past.Cyprotex (CRX) is moving in the right direction and their R&D product delivery and commercialisation is much more attractive - I pointed it out here when it was about 60p on this board - now about 135p. I hope TRX comes good for all holders - but my take is that investors may have a fairly long wait. Good luck all :) Read Full Thread Follow Reply
30/6/2016 08:13	bamboo2: Could be interim results from Meniscus trial as soon as next week. =========================================== 30 June 2016 Tissue Regenix Group plc Deferred Annual Bonus Scheme Leeds, 30 June 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Company") the regenerative medical devices company announces that an award has been made to Ian Jefferson, Chief Financial Officer and Antony Odell, Chief Executive Officer, pursuant to the terms of the Company's Deferred Annual Bonus Scheme. Under the terms of the Deferred Annual Bonus Scheme, Ian Jefferson waived his entitlement to receive 50% of his annual cash bonus in return for an option over 209,677 ordinary shares of 0.5p each in the Company and Antony Odell waived his entitlement to receive 36% of his annual cash bonus in return for an option over 255,484 ordinary shares of 0.5p each in the Company (the "Deferred Allocation"). The number of shares comprising the Deferred Allocation (i.e. subject to option) was calculated by dividing the amount of cash bonus waived by the closing market value of the ordinary shares of the Company on the dealing day immediately prior to the date of deferral. The Deferred Allocation option is not capable of exercise until the vesting date has been reached, which is three years from the date of the award. By participating in the Deferred Annual Bonus Scheme Ian Jefferson and Antony Odell are entitled to receive a matching award at no additional cost (the "Matching Allocation"), being an option over 629,031 and 766,452 ordinary 0.5p shares in the Company respectively. The Matching Allocation is not capable of exercise until the vesting date has been reached, which is three years from the date of award. Additionally, the Matching Allocation is not capable of exercise until the Company's share price has reached the following target prices and remained at those prices for at least 30 consecutive days: Performance criteria % Of Interest .Share Price To Vest ..........Criteria -------------- ------------ 33.33% .........20p -------------- ------------ 33.33%......... 25p -------------- ------------ 33.33%......... 30p -------------- ------------ Read Full Thread Follow Reply
02/1/2014 12:50	multibagger: Hi BB2...my discussion and points of view are largely academic....market seems to be supportive of an upward trending TRX share price and I am certainly not complaining :) The market is what matters and decides the share price, not my opinion ! Read Full Thread Follow Reply

Tissue Regenix share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:40 V: D:20180422 20:20:39